Provided by Tiger Fintech (Singapore) Pte. Ltd.

AtriCure

31.41
-0.3500-1.10%
Volume:61.01K
Turnover:1.92M
Market Cap:1.55B
PE:-38.78
High:31.90
Open:31.66
Low:31.26
Close:31.76
Loading ...

AtriCure Is Maintained at Overweight by JP Morgan

Dow Jones
·
11 Feb

AtriCure price target raised to $51 from $40 at JPMorgan

TIPRANKS
·
11 Feb

Exploring Analyst Estimates for AtriCure (ATRC) Q4 Earnings, Beyond Revenue and EPS

Zacks
·
11 Feb

AtriCure Price Target Maintained With a $60.00/Share by JMP Securities

Dow Jones
·
10 Feb

JMP Securities Reaffirms Their Buy Rating on Atricure (ATRC)

TIPRANKS
·
10 Feb

Earnings Preview: Bio-Rad Laboratories (BIO) Q4 Earnings Expected to Decline

Zacks
·
06 Feb

Will AtriCure (ATRC) Report Negative Earnings Next Week? What You Should Know

Zacks
·
05 Feb

Why AtriCure, Inc. (ATRC) Is Skyrocketing Now

Insider Monkey
·
24 Jan

Revenues Tell The Story For AtriCure, Inc. (NASDAQ:ATRC) As Its Stock Soars 29%

Simply Wall St.
·
23 Jan

AtriCure price target raised to $51 from $40 at Needham

TIPRANKS
·
22 Jan

Brainsway (BWAY) Moves 8.0% Higher: Will This Strength Last?

Zacks
·
22 Jan

AtriCure Is Maintained at Buy by Needham

Dow Jones
·
22 Jan

Analysts Conflicted on These Healthcare Names: Atricure (ATRC) and Hims & Hers Health (HIMS)

TIPRANKS
·
22 Jan

Calculating The Fair Value Of AtriCure, Inc. (NASDAQ:ATRC)

Simply Wall St.
·
15 Jan

AtriCure’s Strong Performance and Promising Outlook Justify Buy Rating Amid Competitive Pressures

TIPRANKS
·
14 Jan

AtriCure Shares Rise After Higher Q4, 2024 Revenue Projections; 2025 Revenue Outlook Set

MT Newswires Live
·
14 Jan

AtriCure Price Target Maintained With a $40.00/Share by Needham

Dow Jones
·
13 Jan

ATRC Receives Buy Rating Due to Strong Financial Performance and Positive Growth Projections

TIPRANKS
·
13 Jan

AtriCure Projects Strong Revenue Growth for 2024

TIPRANKS
·
13 Jan

BRIEF-AtriCure Q4 Revenue USD 124.3 Million Vs. IBES Estimate USD 119.9 Million

Reuters
·
13 Jan